Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60612, USA.
Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, 60612, USA.
Pharm Res. 2022 Nov;39(11):2673-2698. doi: 10.1007/s11095-022-03328-5. Epub 2022 Jul 7.
In the past five decades, red blood cells (RBCs) have been extensively explored as drug delivery systems due to their distinguishing potential in modulating the pharmacokinetic, pharmacodynamics, and biological activity of carried payloads. The extensive interests in RBC-mediated drug delivery technologies are in part derived from RBCs' unique biological features such as long circulation time, wide access to many tissues in the body, and low immunogenicity. Owing to these outstanding properties, a large body of efforts have led to the development of various RBC-inspired strategies to enable precise drug delivery with enhanced therapeutic efficacy and reduced off-target toxicity. In this review, we discuss emerging concepts and new advances in such RBC-inspired strategies, including native RBCs, ghost RBCs, RBC-mimetic nanoparticles, and RBC-derived extracellular vesicles, for drug delivery.
在过去的五十年中，由于红细胞（RBC）在调节携带物的药代动力学、药效学和生物活性方面具有独特的潜力，因此被广泛探索作为药物传递系统。人们对 RBC 介导的药物传递技术的广泛兴趣部分源于 RBC 独特的生物学特性，如长循环时间、广泛进入体内许多组织以及低免疫原性。由于这些出色的特性，大量的努力导致了各种受 RBC 启发的策略的发展，这些策略能够实现精确的药物传递，提高治疗效果，降低脱靶毒性。在本文中，我们讨论了用于药物传递的受 RBC 启发的策略的新兴概念和新进展，包括天然 RBC、ghost RBC、RBC 模拟纳米颗粒和 RBC 衍生的细胞外囊泡。
